ESID
  • Users Online: 67
  • Print this page
  • Email this page
 
CASE REPORT
Ahead of Print

Eosinophilic fasciitis in a patient treated by atezolizumab for metastatic triple-negative breast cancer


1 Department of Medical Oncology, Institute Jules Bordet – ULB, Brussels, Belgium
2 Department of Rhumatology, UZ Ghent, Ghent, Belgium
3 Department of Rhumatology, UZ Ghent; Department of Internal Medicine, Ghent University; VIB Inflammation Research Center (IRC), Unit for Molecular Immunology and Inflammation, Ghent, Belgium
4 Department of Dermatology, UZ Ghent, Ghent, Belgium
5 Department of Radiology, UZ Ghent, Ghent, Belgium
6 Department of Medical Oncology, Institute Jules Bordet – ULB; Department of Dermatology; Department of Medical Oncology, Hospital Erasme – ULB; Department of Medical Oncology, UZ Brussel – VUB, Brussels, Belgium

Correspondence Address:
Sandrine Aspeslagh,
Department of Medical Oncology, UZ Brussel - VUB, Brussels
Belgium
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/JIPO.JIPO_8_19

Immune checkpoint inhibition has revolutionized the treatment for numerous cancer patients; however, the spectrum of immune-related adverse events (irAEs) remains to be fully uncovered. We report a 48-year-old woman who was treated in the Phase III IMpassion130 study (atezolizumab and nanoparticle albumin-bound [nab]-paclitaxel) for metastatic triple-negative breast cancer. She experienced a partial response after 3 months. Nevertheless, the patient presented with thickening of the skin and muscle fatigue in the distal extremities together with blood eosinophilia after 15 months. Skin biopsy and magnetic resonance imaging were diagnostic of eosinophilic fasciitis (EF). Symptoms clearly improved upon stopping atezolizumab, while tumor response is still ongoing after discontinuing treatment. We identified five other cases of EF during immunotherapy, all occurring after about 1 year and in contrast to our case, mostly accompanied by other irAEs. This highlights that even if EF is a rare irAE, timely recognition and management remains important.


Print this article
Search
 Back
 
  Search Pubmed for
 
    -  Wissam Y
    -  Belcaid L
    -  Wittoek R
    -  Smith V
    -  Vanhaecke A
    -  Schepper SD
    -  Jans L
    -  Roodenbeke Dt
    -  Gombos A
    -  Aspeslagh S
 Citation Manager
 Article Access Statistics
 Reader Comments
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed178    
    PDF Downloaded8    

Recommend this journal